Oishi M, Tanaka N, Orita K
First Department of Surgery, Okayama University Medical School, Japan.
Transpl Int. 1996;9 Suppl 1:S100-4. doi: 10.1007/978-3-662-00818-8_26.
The vasodilative action of prostaglandin E1 (PGE1) on the systemic and pulmonary circulation was investigated in swine models of orthotopic liver transplantation. In the PGE1-treated group (n = 8), PGE1 (0.05 microgram/kg per minute) was intravenously infused from the onset of the anhepatic stage to 30 min after revascularization. During the anhepatic stage, PGE1 decreased systemic vascular resistance without a corresponding hypotension, so cardiac output was maintained at a higher level. In the control group (n = 8), pulmonary vascular resistance increased to 3 times the anhepatic value during reperfusion, accompanied by a decline in cardiac output with a 28% decrease in blood pressure. In the PGE1-treated group, on the other hand, pulmonary vascular resistance was maintained within the normal range without any associated decrease in cardiac output. The blood pressure decreased slightly by 12%. In conclusion, in this model, PGE1 increased cardiac output without hypotension during the anhepatic stage and also prevented postreperfusion pulmonary hypertension and the subsequent systemic hypotension.
在原位肝移植猪模型中研究了前列腺素E1(PGE1)对体循环和肺循环的血管舒张作用。在PGE1治疗组(n = 8)中,从无肝期开始至血管再通后30分钟静脉输注PGE1(0.05微克/千克/分钟)。在无肝期,PGE1降低体循环血管阻力而无相应的低血压,因此心输出量维持在较高水平。在对照组(n = 8)中,再灌注期间肺血管阻力增加至无肝期值的3倍,同时心输出量下降,血压下降28%。另一方面,在PGE1治疗组中,肺血管阻力维持在正常范围内,且心输出量无任何相关下降。血压略有下降,降幅为12%。总之,在该模型中,PGE1在无肝期增加心输出量而无低血压,并且还预防了再灌注后肺动脉高压及随后的体循环低血压。